Replies to post #175906 on Biotech Values

[DewDiligence]

Due to GILD’s including a mix of GT1a/GT1b in all three ‘ION’ studies and its including a mix of cirrhotic/non-cirrhotic patients in ION-1 and ION-2 (#msg-96696670), EASL will afford ample opportunities for investors to argue the relative merits of the two datasets based on various criteria. It should keep this board pretty active for a few days!